Rapid Assessment of Cardiovascular Risk Among Users of Smoking Cessation Drugs Within the US Food and Drug Administration's Mini-Sentinel Program | Cardiology | JAMA Internal Medicine | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.206.177.17. Please contact the publisher to request reinstatement.
1.
 FDA Drug Safety Communication: Chantix (varenicline) may increase the risk of certain cardiovascular adverse events in patient with cardiovascular disease. US Food and Drug Administration. Published June 16, 2011. http://www.fda.gov/Drugs/DrugSafety/ucm259161.htm. Accessed September 19, 2011
2.
Rigotti NA, Pipe AL, Benowitz NL, Arteaga C, Garza D, Tonstad S. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial.  Circulation. 2010;121(2):221-22920048210PubMedGoogle ScholarCrossref
3.
Behrman RE, Benner JS, Brown JS, McClellan M, Woodcock J, Platt R. Developing the Sentinel System—a national resource for evidence development.  N Engl J Med. 2011;364(6):498-49921226658PubMedGoogle ScholarCrossref
4.
Platt R, Carnahan RM, Brown JS,  et al.  The U.S. Food and Drug Administration's Mini-Sentinel program: status and direction.  Pharmacoepidemiol Drug Saf. 2012;21:(suppl 1)  1-822262586PubMedGoogle Scholar
5.
Toh S, Reichman ME, Houstoun M,  et al.  Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system [published online October 15, 2012].  Arch Intern Med. 2012;172(20):1582-158923147456PubMedGoogle ScholarCrossref
6.
McGraw D, Rosati K, Evans B. A policy framework for public health uses of electronic health data.  Pharmacoepidemiol Drug Saf. 2012;21:(suppl 1)  18-2222262589PubMedGoogle ScholarCrossref
7.
Mini-Sentinel.  Modular program report: smoking cessation drugs and cardiovascular outcomes. http://www.mini-sentinel.org/work_products/Assessments/Mini-Sentinel_Smoking-Cessation-Drugs-and-Selected-Cardiovascular-Outcomes.pdf. Published January 17, 2012. Accessed January 23, 2012
8.
Singh S, Loke YK, Spangler JG, Furberg CD. Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis.  CMAJ. 2011;183(12):1359-136621727225PubMedGoogle ScholarCrossref
9.
Prochaska JJ, Hilton JF. Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis.  BMJ. 2012;344:e285622563098PubMedGoogle ScholarCrossref
Research Letter
May 13, 2013

Rapid Assessment of Cardiovascular Risk Among Users of Smoking Cessation Drugs Within the US Food and Drug Administration's Mini-Sentinel Program

Author Affiliations

Author Affiliations: Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts (Drs Toh, Baker, Brown, and Platt); and Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland (Dr Kornegay).

JAMA Intern Med. 2013;173(9):817-819. doi:10.1001/jamainternmed.2013.3004

In June 2011, the US Food and Drug Administration (FDA) issued a Drug Safety Communication indicating that varenicline tartrate, a drug prescribed for smoking cessation, may increase the risk of certain cardiovascular events in individuals with cardiovascular disease.1 The finding was based on the FDA's review of a randomized placebo-controlled trial of 714 smokers.2 In July 2011, the FDA requested that the Mini-Sentinel program perform a rapid safety assessment of the drug.

Mini-Sentinel is part of the FDA's Sentinel Initiative, a national system under development for monitoring medical product safety.3-5 The program has created a distributed network of electronic health care databases with more than 125 million lives and 350 million person-years of longitudinal observation time.

×